Gross Margin

Medical device firm CVRx is under investigation after its stock nosedived. Did management mislead investors about its salesforce stability?

TNL Mediagene's GIZMART platform and Keychron smash crowdfunding records, proving editorial trust can be a powerful driver of direct-to-consumer sales.

The first-ever Wegovy pill is now available via telehealth platform Ro, offering a cash-pay option that could revolutionize access to weight loss drugs.

OpenText divests its on-premise eDOCS unit to NetDocuments, using the cash for debt reduction while sharpening its focus on AI and cloud services.

Amid rapid industry consolidation, doctor-owned DSO PepperPointe Partnerships adds three VPs to scale its unique model and support continued expansion.

This strategic acquisition combines AI-driven tech with deep clinical expertise to help hospitals fight rising claim denials and severe margin pressure.

Inogen reports modest growth and a pivotal return to positive EBITDA, yet a revenue miss from delayed B2B orders raises questions for its turnaround.

New 2025 data reveals an AI platform is slashing costs, improving chronic disease outcomes, and closing health equity gaps for hundreds of clinicians.

Kyle Addington of American Wealth Advisers joins IFG's new advisory council, giving local clients a voice in the future of financial services nationwide.

Carlsmed's AI-driven aprevo® platform shows massive surgeon adoption and market growth, signaling a new era of personalized, cost-effective spine care.

With preliminary Q1 revenue of $103.7M, Twist Bioscience beats forecasts, setting a bullish tone ahead of its full earnings report on February 2nd.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

Amidst a strategic push for profitability, CytoSorbents advances its DrugSorb-ATR device, aiming to revolutionize safety in cardiac surgery.

Utz Brands posted strong 2025 profit growth and market share gains, overcoming retail inventory issues caused by economic headwinds like SNAP delays.

Cytek Biosciences reports preliminary 2025 revenue of $201M, beating estimates with a major Q4 growth surge ahead of its key J.P. Morgan presentation.

With booming revenue, a potential blockbuster on the horizon, and key partnerships, Ascendis Pharma lays out a bold roadmap for global dominance.

Beyond a simple time change, Fortrea's upcoming JPM presentation is a critical test for its new CEO and a key moment to define its future in the CRO market.

The automotive giant honored its top vendors, signaling that deep strategic partnerships are crucial to its ongoing operational and financial transformation.

Prescryptive and Ilant Health unveil a direct-to-employer model for obesity drugs, promising transparent pricing and better clinical outcomes for employers.

With 11 straight quarters of growth and a focus on 'Physical AI,' lidar leader Ouster is set to detail its ambitious strategy for institutional investors.